A 52-week, randomized, open-label, parallel-group, phase 3a trial with real-world elements was conducted at 176 sites in seven countries. A total of 1085 insulin-naive patients with type 2 diabetes ...

BAGSVAERD, Denmark, Sept. 22, 2020 /PRNewswire/ -- Today, Novo Nordisk announced results from three phase 2 clinical trials for insulin icodec, an investigational once-weekly basal insulin analogue, ...

In individuals with type 2 diabetes with no previous insulin treatment, once-weekly injections of insulin icodec resulted in glucose-lowering efficacy and a safety profile similar to individuals who ...

For millions of patients with diabetes, daily insulin injections are a necessary nuisance. A once-a-week shot might be more palatable, and new results from phase 2 clinical trials suggest just such a ...

Over the course of 52 weeks, people with type 2 diabetes saw a greater average reduction in HbA1c with icodec compared with glargine U100 (estimated between-group difference -0.19%, 95% CI -0.36% to ...

Phase 2 data for the investigational, once-weekly basal insulin analog icodec (Novo Nordisk) showing comparable efficacy and safety to once-daily insulin glargine U100 have been published in the New ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A combination therapy of insulin icodec and semaglutide ...

Compared with once-daily comparators, once-weekly icodec was associated with similar safety and efficacy outcomes regardless of race, ethnicity, or age. The hypoglycemic profile and efficacy of ...

Bagsværd, Denmark, 29 July 2022 – Novo Nordisk today announced headline results from the ONWARDS 3 and ONWARDS 4 phase 3a trials with once-weekly insulin icodec in adults with type 2 diabetes. The ...

U.S. FDA scientists said that there is a risk that Novo Nordisk's (NVO) once-weekly insulin icodec, under investigation for type 1 and type 2 diabetes, can lead to extremely low blood sugar levels. In ...